Long‐Term Metabolic Consequences of Switching from Protease Inhibitors to Efavirenz in Therapy for Human Immunodeficiency Virus–Infected Patients with Lipoatrophy

Vicente Estrada(Instituto de Salud Carlos III), Manuel Serrano‐Ríos(Real Academia Española), Cristina Fernández(Universidad Complutense de Madrid), Amparo González López, Noemí González Pérez de Villar(Hospital Clínico San Carlos), M. T. Martínez Larrad(Hospital Clínico San Carlos)
Clinical Infectious Diseases
July 1, 2002
10.1086/340863
Cited by 48

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
A functional variant of SUMO4, a new IκBα modifier, is associated with type 1 diabetes
|Nature Genetics|2004|423
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343